![More History of the 503B and 503A Bulk Drug Substance Lists Significant and Welcomed Changes_LachmanBlog](https://www.lachmanconsultants.com/wp-content/uploads/2023/12/More-History-of-the-503B-and-503A-Bulk-Drug-Substance-Lists-Significant-and-Welcomed-Changes_LachmanBlog-scaled.jpg)
More History of the 503B and 503A Bulk Drug Substance Lists: Significant and Welcomed Changes?
Last week, the FDA has announced the availability of two draft Guidances for Industry regarding compounding of human drugs: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (here); and Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and […]